U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H16F3IN2O2
Molecular Weight 476.2315
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PD-198306

SMILES

CC1=CC(I)=CC=C1NC2=C(F)C(F)=C(F)C=C2C(=O)NOCC3CC3

InChI

InChIKey=UHAXDAKQGVISBZ-UHFFFAOYSA-N
InChI=1S/C18H16F3IN2O2/c1-9-6-11(22)4-5-14(9)23-17-12(7-13(19)15(20)16(17)21)18(25)24-26-8-10-2-3-10/h4-7,10,23H,2-3,8H2,1H3,(H,24,25)

HIDE SMILES / InChI

Molecular Formula C18H16F3IN2O2
Molecular Weight 476.2315
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12642375 | https://encrypted.google.com/patents/WO1998037881A1 | http://www.google.com.na/patents/WO2001005390A3

PD-198306 is a cell-permeable, amino-benzamide derivative that acts as a potent and non-ATP-competitive inhibitor of MEK1/2 with an excellent selectivity over ERK, c-Src, Cdk's, and phosphatidylinositol 3-kinase γ. In vitro PD-198306 inhibits MEK activity in synovial fibroblasts at concentrations of 30–100 nM, depending on the species. PD 198306 has a bioavailability of 62% when taken orally and is active in several animal models of rheumatoid arthritis, including rat streptococcal cell wall-induced arthritis and rat adjuvant arthritis. PD 198306 can partially decrease the development of some of the structural changes in experimental osteoarthritis model. PD 198306 dose-dependently blocked static allodynia in both the streptozocin and the chronic constriction injury (CCI) models of neuropathic pain. The antihyperalgesic effects of PD 198306, in both the streptozocin and CCI models of neuropathic pain, correlated with a reduction in the elevated levels of active ERK1 and 2 in a lumbar spinal cord.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.
2013-03
Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and 5-HT(2A) receptors.
2013-02
Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D₂ receptors in rat prefrontal cortex.
2012-10
Identification of MEK1 as a novel target for the treatment of neuropathic pain.
2003-03
Patents

Sample Use Guides

New Zealand male rabbits were treated with PD 198306 at dosages of 10 mg/kg/day or 30 mg/kg/day for 8 weeks. PD 198306 was administered once daily at 8:00 AM as a liquid solution, by oral gavage into the stomach.
Route of Administration: Oral
T47D cells were used for evaluation the effect of MEK inhibitor PD-198306 on ERK phosphorylation upon treatment with different doses of EGF. Cells were preincubated with PD 198306 (200 nM) for 30 min and stimulated with EGF (1 nM) for the 2, 5, 15, 30 ,45, 60, 90 and 120 min. Equal amounts of total cell lysates were resolved by NuPAGE and subjected to Multistrip Western blotting. Immunoblots (IBs) were probed with anti-phospho-p44/42 MAPK (ERK1/2) (labeled as p-ERK).
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:45:25 GMT 2025
Edited
by admin
on Mon Mar 31 22:45:25 GMT 2025
Record UNII
WQ5121ZGT3
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENZAMIDE, N-(CYCLOPROPYLMETHOXY)-3,4,5-TRIFLUORO-2-((4-IODO-2-METHYLPHENYL)AMINO)-
Preferred Name English
PD-198306
Common Name English
N-CYCLOPROPYLMETHOXY-3,4,5-TRIFLUORO-2-(4-IODO-2-METHYLPHENYLAMINO)BENZAMIDE
Systematic Name English
Code System Code Type Description
FDA UNII
WQ5121ZGT3
Created by admin on Mon Mar 31 22:45:25 GMT 2025 , Edited by admin on Mon Mar 31 22:45:25 GMT 2025
PRIMARY
EPA CompTox
DTXSID70433306
Created by admin on Mon Mar 31 22:45:25 GMT 2025 , Edited by admin on Mon Mar 31 22:45:25 GMT 2025
PRIMARY
PUBCHEM
9956637
Created by admin on Mon Mar 31 22:45:25 GMT 2025 , Edited by admin on Mon Mar 31 22:45:25 GMT 2025
PRIMARY
CAS
212631-61-3
Created by admin on Mon Mar 31 22:45:25 GMT 2025 , Edited by admin on Mon Mar 31 22:45:25 GMT 2025
PRIMARY
Related Record Type Details
ACTIVE MOIETY